Ocumetics Technology Announces $2.5 Million Brokered LIFE Offering Led by Centurion One Capital

Executive Summary

• Ocumetics Technology Corp. entered into a brokered private placement agreement with Centurion One Capital Corp. as lead agent and sole bookrunner.
• Up to 3,472,222 units will be sold at $0.72 per unit for gross proceeds of up to $2,500,000; an additional option allows the lead agent to sell up to 520,833 units for up to $375,000.
• Proceeds are earmarked primarily for the company’s first‑in‑human clinical trials, ongoing R&D, and general corporate purposes.

Key Details

• Units Structure: Each unit consists of one common share and one common share purchase warrant.
• Warrant Terms: Warrants allow acquisition of one additional common share at $0.90 per share for three years from the closing date.
• Issue Price: $0.72 per unit (best‑efforts basis).
• Maximum Units Offered: 3,472,222 units → up to $2,500,000 gross proceeds.
• Lead Agent’s Option: Up to 520,833 additional units at the same issue price, providing an extra $375,000 if exercised (exercisable up to two business days before closing).
• Closing Date: Expected on or around December 11, 2025, subject to customary conditions and TSX Venture Exchange approval.
• Use of Proceeds: Primarily to fund first‑in‑human clinical trials, support ongoing research & development, and for general corporate purposes (allocation may vary).
• Exemptions Utilized: Listed issuer financing exemption under NI 45-106 (Canada) and U.S. securities law exemptions; no statutory hold period in Canada.
• Related Party Participation: Insiders of Ocumetics, the lead agent, and affiliates may purchase units; expected to be exempt from MI 61‑101 valuation/approval thresholds (<25% market cap).

Notable Quotes

• “The financing will enable us to advance our groundbreaking intraocular lens technology into first‑in‑human trials, bringing us closer to delivering a vision‑changing solution for patients,” – Dean Burns, President and CEO.